BAK1 and Miyoshi myopathy: Since the combination therapy with BTZ is a good choice to avoid drug resistance than monotherapy, we combined SHP2 inhibitors with BTZ and found synergistic antitumor activity in MM cells with enhanced expression of P21, BAK, and cleaved caspase-3.